RelA-Induced Interferon Response Negatively Regulates Proliferation.

• الحاوية / القاعدة: PLoS ONE
• المؤلفون الرئيسيون: Bose S Kochupurakkal, Zhigang C Wang, Tony Hua, Aedin C Culhane, Scott J Rodig, Koraljka Rajkovic-Molek, Jean-Bernard Lazaro, Andrea L Richardson, Debajit K Biswas, J Dirk Iglehart
• التنسيق: مقال
• اللغة: الإنجليزية
• منشور في: Public Library of Science (PLoS) 2015-01-01
• الوصول للمادة أونلاين: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0140243&type=printable

Both oncogenic and tumor-suppressor activities are attributed to the Nuclear Factor kappa B (NF-kB) pathway. Moreover, NF-kB may positively or negatively regulate proliferation. The molecular determinants of these opposing roles of NF-kB are unclear. Using primary human mammary epithelial cells (HMEC) as a model, we show that increased RelA levels and consequent increase in basal transcriptional activity of RelA induces IRF1, a target gene. Induced IRF1 upregulates STAT1 and IRF7, and in consort, these factors induce the expression of interferon response genes. Activation of the interferon pathway down-regulates CDK4 and up-regulates p27 resulting in Rb hypo-phosphorylation and cell cycle arrest. Stimulation of HMEC with IFN-γ elicits similar phenotypic and molecular changes suggesting that basal activity of RelA and IFN-γ converge on IRF1 to regulate proliferation. The anti-proliferative RelA-IRF1-CDK4 signaling axis is retained in ER+/HER2- breast tumors analyzed by The Cancer Genome Atlas (TCGA). Using immuno-histochemical analysis of breast tumors, we confirm the negative correlation between RelA levels and proliferation rate in ER+/HER2- breast tumors. These findings attribute an anti-proliferative tumor-suppressor role to basal RelA activity. Inactivation of Rb, down-regulation of RelA or IRF1, or upregulation of CDK4 or IRF2 rescues the RelA-IRF1-CDK4 induced proliferation arrest in HMEC and are points of disruption in aggressive tumors. Activity of the RelA-IRF1-CDK4 axis may explain favorable response to CDK4/6 inhibition observed in patients with ER+ Rb competent tumors.